Fungal Foot-Animal Market

Key data points: Market size in 2027 = $1.4 billion and 2035 = $2.1 billion, growth forecast = 5.8% annually for the next 8 years. Scroll below to get more insights. This market report covers trends, opportunities and forecasts in fungal foot-animal market to 2035 by animal type (dogs, cats, and others), treatment type (topical medications, oral medications, and home remedies), product form (creams & ointments, powders, sprays, tablets & capsules, and others), end use (individual consumers, veterinary clinics, hospitals, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World) Fungal Foot-Animal Market The future of the global fungal foot-animal market looks promising with opportunities in the individual consumer, veterinary clinic, and hospital markets. The global fungal foot-animal market is expected to reach an estimated $2.1 billion by 2035 from $1.4 billion in 2027 with a CAGR of 5.8% from 2027 to 2035. The major drivers for this market are the increasing incidence of fungal infections, the rising awareness about pet health issues, and the growing demand for veterinary treatments. • Lucintel forecasts that, within the treatment type category, topical medications is expected to witness the highest growth over the forecast period due to ease of use and the certain kind of relief offered by topical medications. • Within the end use category, veterinary clinics is expected to witness the highest growth over the forecast period due to increased cases of pet fungal infections treated at veterinary facilities. • In terms of regions, APAC is expected to witness the highest growth over the forecast period due to increased ownership of pets and awareness of fungal infections of pets. Gain valuable insights for your business decisions with our comprehensive 150+ page report. Sample figures with some insights are shown below. Emerging Trends in Fungal Foot-Animal Market The fungal market is transitioning to more prevention-based strategies from 2025 to 2027. More veterinary clinics are using strategies to prevent and control fungal infections. Fungal infections of livestock are becoming more problematic, and strategies to combat these infections are becoming more of a focus. Lucintel believes that during this time frame, improvements to and the development of new partnerships to distribute fungal infection prevention products will be of great importance. • Preventive Herd Health: The prevention of fungal infections of livestock is becoming more of a focus. During 2025, many livestock operations began to prevent fungal infections by cleaning the stalls and using antifungal sprays to treat the livestock. Many operations began to inspect the livestock and treat the livestock every 2 to 4 weeks. It is less costly to treat and prevent fungal infections than it is to treat the infections if they become frequent. • Diagnostic Led Treatment: Many farmers have begun to use culturing and other diagnostic tests to determine if their livestock has been infected by a fungus. Using these tests assists the farmers in making an informed decision on if they should treat their livestock. Many farmers are switching to these diagnostic tests in 2026. Diagnostic tests allow farmers to evaluate if the treatment they are giving their livestock is actually helping. • Formulation Convenience: Many companies are creating antifungal products that are easier to use and that have a longer contact time. These products are being created for both livestock and companion animals. These products are focusing on reducing the time it takes to treat an animal to be less than 10 minutes. Improving these products will be important to maintain a competitive edge through 2030. • Sustainability Pressure: In 2025, potential buyers raised concerns regarding high solvent loads, excessive product packaging, and waste. Concurrently, suppliers began to evaluate lower-waste packaging and dosing systems. In 2025 and 2026, disruptions in the pharmaceutical and related packaging supplies negatively impacted the veterinary market. The disruptions were attributed to the lack of supply chain resilience. During the same period, many veterinary clinics and farms reviewed their procurement processes. Environmental considerations were incorporated into the reviews. • Resilience of The Regional Supply: A greater number of suppliers located in diverse countries began to manufacture veterinary pharmaceuticals in 2025 and 2026. As a result, many suppliers began to manufacture veterinary pharmaceuticals in more than one country. Some veterinary clinics and pharmacies began to maintain a 2-to-3-month supply of veterinary pharmaceuticals, especially if the manufacture and supply of the product was fragmented. During the next five years, there will be an increased concern regarding antifungal activity and the prevention of fungal infections. Preventive measures should be economical, easy to use, and integrate well into the daily activities of the veterinary practice. Based on the activities of pharmaceutical companies, various diagnostics and technologies will be integrated into veterinary medicine. Recent Developments in the Fungal Foot-Animal Market The widespread prevalence of fungal pathogens in the animal kingdom accelerated the need for pharmaceutical and diagnostic solutions in the vet market during the 2025-2026 time frame. Antimicrobial stewardship initiatives, combined with the rise in veterinary diagnostic and antifungal solutions, created a more favorable environment for fungal pathogen control in animal health. Demand for such solutions exists for all animal levels (companion, livestock, and equine). However, regulatory disparities international and nationally hinder the introduction of related products. First generation solutions target fungal pathogens in the animal health industry. • Advances in Diagnostic Testing: In January 2025, IDEXX reported $1.03 billion in revenue from its animal health and veterinary products and services. The company noted strong demand for veterinary diagnostic testing. New diagnostic tests targeting dermatophytes and other yeast infections will likely improve clinical and economic outcomes for veterinary practices. • Antifungal Drug Approval: In March 2025, the U.S. Food and Drug Administration (FDA) approved Claro for the treatment of otitis externa in dogs. Claro is a combination of Florfenicol, Terbinafine, and Mometasone. • Investments in Veterinary Health: In February 2025, Zoetis announced it anticipated 2024 revenue of $9.3 billion, and further committed to expanding its investments in veterinary health. Expansion in the veterinary health market raises the competitive barriers for smaller animal health companies. • Partnerships: Elanco and other veterinary partners expanded their digital offerings for clinical decisions in companion-animal practices. Digital records and other features enabled the measurement of antifungal product effectiveness. This type of real-world evidence builds confidence in product performance and supports its use. • Stiffening Regulations: In the EU, the EMA implemented regulations concerning the control of antimicrobial products for veterinary use (2019/6). The amendment created more stringent controls. As a result, pharmaceutical companies will need to provide additional evidence of a product’s safety and ensure the product meets specific standard operating procedures for use. These procedures will be implemented for food-producing animals. Increased reliance on science and data to inform treatment will enhance the use of effective antifungal therapies to treat fungal infections and reduce the use of broad-spectrum, antimicrobial therapies. Meeting these therapeutic needs will be addressed by large, vertically integrated companies and negatively impact small companies that are merely product distributors. Strategic Growth Opportunities in the Fungal Foot-Animal Market More and more customers are interested in preventing fungal infections than in treating them. There is also interest in quicker diagnostic services and the protection of farm production from fungal infections. Around 2024-2026, the farm industry is expected to experience better control of the spread of diseases among farm animals. Based on Lucintel's market analysis, it would be prudent for pharmaceutical companies to develop anti-fungal products specifically for the prevention and treatment of animal fungal infections. • Preventive Products: In 2025, a supplier of veterinary products based in Europe, reported a 14% increase in sales of preventive products for the care of animal hooves. It is expected that preventive products for the care of hooves and other body parts of animals will continue to be in high demand during the next several years. • Rapid Diagnostic Services: In 2026, a veterinary laboratory at a university reported that it was able to identify fungal infections in less than 2 days using molecular services. It is expected that services for the identification of fungal infections will facilitate the rapid selection of treatments and the periodic monitoring of the health of farm animals. • Premium Products: In 2025, a contract manufacturer of veterinary products reported the release of a hoof product containing three active ingredients. It is expected that in the next several years, the farming industry will be in the market for products that control fungal infections in animals in order to improve the health and speed the recovery of the animals. • Aquaculture: In April 2025, 2,000 fish in a local aquaculture program were diagnosed with fungal infections and treated accordingly. Veterinary suppliers can help prevent and treat fungal infections in fish, as well as other companion and captive animals. This would create a different source of income for the supplier and help establish a presence in these markets. • Animal Monitoring: In January 2026, a client in the precision livestock sector used the supplier’s camera systems to assess and monitor the movement of 10,000 animals. Suppliers should aim for integration across the value chain. In this instance, software that automatically detects lesions and alerts the user for potential treatment would allow the supplier to enter a new market and develop additional sources of income. Products that address farm economics and improve farm operations should be successful. Likely the most successful products will be those that improve the farm’s bottom line by reducing operating expenses and enhancing efficiency. These products should also maintain customer loyalty. In the coming years, the most successful companies will be integrators that provide animal diagnostics, health and wellness products and services. Fungal Foot-Animal Market Drivers and Challenges Continued concern for sustainability, combined with increased awareness for the health and welfare of livestock, advanced diagnostics and therapeutics, and changes in the veterinary infrastructure, provide growth opportunities for fungal infections animal diseases. So do changes in the regulations that affect the use of antimicrobials. There continues to be a growing demand for affordable, effective, and safe fungal disease management products for all animals. According to Lucintel, this is particularly true for livestock, companion animals, and other animals used for therapeutic and other purposes. The factors responsible for driving this market include: • Customer Awareness: Veterinarians, livestock producers, and pet owners have become more aware of fungal diseases and the need for preventive measures. As farming methods have changed to increase productivity, livestock have come into closer contact with humans and other livestock, increasing the risk of infection. Consequently, preventive measures and treatments for fungal infections of the skin and feet have become more widespread. In June 2025, the World Organisation for Animal Health (OIE) continued its efforts to enhance animal health and disease surveillance systems in over 180 member countries. It is expected that awareness for animal health and welfare will increase in the same member countries in the next 3-5 years. This is expected to lead to an increase in the use of preventive measures and greater demand for diagnostic services and products. • Diagnostic Technology: Traditionally, fungal infections in animals were diagnosed primarily by the veterinarian’s inspection of clinical samples. More recently, advances in diagnostic technology have enabled better identification of fungal infections. Additionally, the development of digital veterinary platforms has enabled diagnostic imaging from remote locations. New molecular diagnostics enable veterinarians to test for multiple pathogens using a single sample. Reduced delays in identification and diagnosis of fungal infections have created a greater need for antifungal therapies. In 2025, multiplex pathogen tests became even more accessible and led to an increase in the diagnosis of fungal infections. It is expected that the next few years will see additional advances in veterinary diagnostic testing, which are more affordable and accessible, and result in an increase in the identification and diagnosis of fungal infections. • Product Development: There has been considerable advancement in the formulations and methods of delivery of anti-fungal products for animals. These have included combinations of anti-fungal products with other active ingredients. Advances in formulations and methods of delivery have allowed for the design of products that reduce the frequency of treatment and increase skin penetration. Improvements in product formulations, packaging, and delivery systems have improved the ease of administration of veterinary products. It is expected that the next few years will see advances in the anti-fungal products for the treatment of fungal infections in animals that will allow veterinarians to charge a premium for improved products. • Regulatory Support: Fungal foot treatments benefit from indirect regulation concerning the responsible use of antimicrobials. When the EU supported the use of veterinarians to diagnose and treat farm animal diseases, the farmers showed a preference for the prescribed antifungal treatments. The farmers of the EU no longer used antibiotics or traditional remedies to treat their livestock. As of February 2025, the EU continued to have a framework for the regulation of 27 member states to support the veterinary regulations. Until 2025, some member states of the EU continued to revise and harmonize their veterinary regulations. These changes should make the vet regulations more consistent, which would reduce business uncertainty and increase the demand for diagnosed and regulated solutions for fungal diseases. • Manufacturing Efficiency: From April 2025, the continued focus on automation by the pharmaceutical industry improved the traceability of batch production and reduced errors by pharmacies. Continued specialization in manufacturing improved competitiveness and quality of pharmaceuticals, which benefited the supply and availability of fungal treatments. The improved manufacturing standards combined with increasing support for automation should improve the availability of fungal treatments and reduce costs, making them accessible for use on smaller farms and pets. The challenges facing this market include: • Diagnostic Difficulty: Multiple causes and symptoms of fungal infections of the foot are similar to various bacterial, allergic, parasitic, traumatic and nutritional conditions, limiting the possibilities for an accurate diagnosis. Rural isolation, a lack of laboratories and qualified veterinarians may contribute to an incorrect diagnosis and unjustified use of antifungal products. In 2025, many veterinary surveillance programs were conducted without laboratory aids. Because of this situation, many farmers remain sceptical and uncertain with regard to prevention and control measures against fungal infections. Affordable and reliable diagnostic tests and the continuing professional development of veterinarians are expected to reduce diagnostic complexity and accelerate the use of antifungal products in animal health. • Treatment and Resistance: Poor farm biosecurity, inadequate and incorrect use of antifungal products and farm hygiene increase the level of fungal infections and encourage the development of fungal infections. In 2025, numerous veterinary stewardship and antimicrobial resistance programs focused on prudent and proper use of antimicrobials and other products across the various livestock species. Poor and unjustified use of veterinary antimicrobial products are the key reasons for development of antibiotic and antifungal resistance. Products lacking adequate and proper instructions for veterinary use may remain off the market. • Cost and Market Fragmentation: Small and fragmented farms, together with informal animal health markets and unequal distribution of veterinary services, create fragmented and difficult to identify market demands. Often times, farmers will opt to use low-cost or informal animal health products, even if the cost to use a veterinary product is affordable. A number of factors can influence the cost of veterinary products, including volatility of local currencies and supply disruptions. Active pharmaceutical ingredients and finished veterinary products can be expensive. Price differences for agricultural inputs persisted across the globe in 2025. It is expected that, at least in the short to medium term, price will be the main constraint on the use of veterinary products, particularly in lower and middle income countries. There are a number of positive trends in the veterinary foot-health market including increasing awareness of animal health, formulations, and regulations. Manufacturing is also becoming more efficient. These factors are expected to increase the use of veterinary products. The market will gain most in areas with greater livestock density and pet ownership. The market is expected to grow most in regions with adequate veterinary infrastructure and services. List of Fungal Foot-Animal Market Companies Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies fungal foot-animal market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the fungal foot-animal market companies profiled in this report include- • Bayer • GSK • Johnson & Johnson • Novartis • Bausch Health • TEVA • Taro Pharmaceutical • WellSpring Pharma • Crown Laboratories • Medimetriks Pharmaceuticals Fungal Foot-Animal Market by Segment The study includes a forecast for the global fungal foot-animal market by animal type, treatment type, product form, end use, and region. Fungal Foot-Animal Market by Animal Type [Value ($B) from 2019 to 2035]: • Dogs • Cats • Others Fungal Foot-Animal Market by Treatment Type [Value ($B) from 2019 to 2035]: • Topical Medications • Oral Medications • Home Remedies Fungal Foot-Animal Market by Product Form [Value ($B) from 2019 to 2035]: • Creams & Ointments • Powders • Sprays • Tablets & Capsules • Others Fungal Foot-Animal Market by End Use [Value ($B) from 2019 to 2035]: • Individual Consumers • Veterinary Clinics • Hospitals • Others Fungal Foot-Animal Market by Region [Value ($B) from 2019 to 2035]: • North America • Europe • Asia Pacific • The Rest of the World Country Wise Outlook for the Fungal Foot-Animal Market Fungal infections of the foot constitute a specialized segment of the animal health market comprising products for the treatment of dermatophytosis and other related mycotic infections as well as associated hoof care products. Notably, these segments are usually not reported in the public domain. From 2025 to 2027, Lucintel anticipates that the animal health market will undergo considerable change as a result of improvements in regulatory, manufacturing and investment climate. Therefore, during this period, projections for individual segments of the market are expected to have more confidence. • United States: The Center for Veterinary Medicine (CVM) of the Food and Drug Administration (FDA) published its priorities for fiscal year 2025 (FY 2025), including initiatives focused on post-market surveillance of veterinary products. We anticipate the CVM’s emphasis on post-market surveillance will facilitate the availability of topical antifungal products. • China: The Veterinary Drug Administration Law of the People’s Republic of China came into effect in January 2025, with the implementation period ending in 2028. We expect the reform will improve the availability and distribution of veterinary products in China. • Germany: German legislation requiring all veterinary medicinal products to comply with the European regulatory standards has been in force since 2021. Boehringer Ingelheim plans to spend more than €100 million by 2025 to manufacture veterinary medicinal products at locations outside of the European Union. German suppliers have strong potential to manufacture and supply (animal) health products and related formulations, and standards. • India: India’s 2024-25 Union Budget increased the allocation to the Department of Animal Husbandry and Dairying to ₹4,521 crore. Control of animal diseases has been prioritized and should enhance the formal veterinary services, thereby creating a market for veterinary antifungal and hoof-care products. • Japan: The controls on animal diseases and on veterinary products for 2025 have been included in the programs of the Ministry of Agriculture, Forestry and Fisheries. Reliable systems for the registration and procurement of veterinary products for use in commercial and companion animals have been established. Features of the Global Fungal Foot-Animal Market Market Size Estimates: fungal foot-animal market size estimation in terms of value ($B). Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions. Segmentation Analysis: fungal foot-animal market size by various segments, such as by animal type, treatment type, product form, end use, and region in terms of value ($B). Regional Analysis: fungal foot-animal market breakdown by North America, Europe, Asia Pacific, and Rest of the World. Growth Opportunities: Analysis of growth opportunities in different animal types, treatment types, product forms, end uses, and regions for the fungal foot-animal market. Strategic Analysis: This includes M&A, new product development, and competitive landscape of the fungal foot-animal market. Analysis of competitive intensity of the industry based on Porter’s Five Forces model. If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more. This report answers following 11 key questions: Q.1. What are some of the most promising, high-growth opportunities for the fungal foot-animal market by animal type (dogs, cats, and others), treatment type (topical medications, oral medications, and home remedies), product form (creams & ointments, powders, sprays, tablets & capsules, and others), end use (individual consumers, veterinary clinics, hospitals, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)? Q.2. Which segments will grow at a faster pace and why? Q.3. Which region will grow at a faster pace and why? Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market? Q.5. What are the business risks and competitive threats in this market? Q.6. What are the emerging trends in this market and the reasons behind them? Q.7. What are some of the changing demands of customers in the market? Q.8. What are the new developments in the market? Which companies are leading these developments? Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth? Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution? Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?